AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron COVID-19 variant, joining other vaccine markers who are looking to develop the variant specific vaccine.
“Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data,” a spokesperson for the company said in a statement, as reported by Reuters.
The Financial Time first reported the news, citing Sandy Douglas who is a leader of a research group at Oxford.
Financial Times noted Doulas said, “Adenovirus-based vaccines (such as that made by Oxford/AstraZeneca) could in principle be used to respond to any new variant more rapidly than some may previously have realized,”.
